The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma

Abstract

Background/aim: Hypertension is a risk factor for occurrence of renal cell carcinoma; however, it remains unclear whether hypertension affects development and prognosis of renal cell carcinoma. This study evaluated the impact of hypertension on the progression of renal cell carcinoma.

Patients and methods: Renal cell carcinoma patients who were treated from October 2007 to December 2018 at our Institution were retrospectively analyzed.

Results: Of 462 patients, the number of patients with and without hypertension was 234 (including 227 treated with anti-hypertensive agents) and 228, respectively. The tumor size was significantly smaller in the hypertension group than in the non-hypertension group (median 32 and 45 mm, respectively, p=0.010). The 5-year cancer-specific and metastasis-free survival in the hypertension group were significantly better than those in the non-hypertension group (93.6% and 80.4%, and 84.6% and 73.0%, respectively, p=0.021 and p=0.017). Propensity score matching revealed significantly better metastatic-free survival in the hypertension group than the non-hypertension group (p=0.022).

Conclusion: Renal cell carcinoma patients with hypertension show better prognosis with low metastasis possibility.

Keywords: Anti-hypertensive agent; hypertension; renal cell carcinoma.